Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 19 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research

Synthetic Chemistry

Medicinal Chemistry

Analytical Chemistry

Full Time Equivalent(FTE)

Fee For Service(FFS)

Catalyst Screening

Enzyme Catalysis

Continuous Flow Chemical Technology

Biology Research

Structural Biology

Cell Biology

Enzymology & Molecular Interactions

Antibody Discovery

Translational Medicine

High Throughput Screening

Computational Biology & Molecular Modeling

Early Pharmacokinetics

Radiolabel ADME

02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients

Route Selection

Production Process Optimization

Clinical Sample Production

Impurity Traceability & Control

Generic Drug Process Study & Filing

Innovative Drug Process Study & Filing

Pharmaceutical preparation

Consistency Evaluation

Preformulation Study

Formulation Stability Study

GMP-based Clinical Sample Production & Packaging

Pilot-scale Preparation Testing

Laboratory-scale Preparation Testing

Preparation Quality Research

Formulation Technology Research

Analytical Method Development and Quality Control
CMC Filings
03 Preclinical Research
Pharmacology & Pharmacodynamics

Tumor Models

Digestive System Disease Models

Endocrine & Metabolic Disease Models

Inflammatory & Immune Diseases Models

Neural System Disease Models

Other Disease Models

PDXO Models

Ocular Diseases Models

Cardiovascular Model

Drug Safety Evaluation

Pharmacology & Toxicology Study

Safety Pharmacology

Histopathological Study

Clinicopathological Study

Drug Safety Evaluation Basic Information

Toxicokinetics

DMPK

In Vitro ADME Assays

In Vivo Pharmacokinetic Assays

Bioanalysis

Macromolecular Drugs Bioanalysis

Micromolecular Drugs Bioanalysis

IND Filings
01 One-stop Integrated Services
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Chemical Drug Development
One-stop API Process R&D Department
CDMO Service Platform
Pharmaceutical Research CDMO Service Platform
Translational Medicine Platform
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
Peptide Drug Conjugate (PDC) R&D Service Platform
Antibody R&D Service
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Safety Assessment Lab of Process Chemistry
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Process Department Solid Form Screening Platform
Green Chemistry Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
Routes of Drug Administration Platform
Drug Solid-State Research Service Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D Platform
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
07 Drug analysis platform
08 Public Services
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 50 Soldiers Field Place, Boston, MA 02135 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2023-10-25Medicilon Events
Medicilon congratulated AnDiCon Biotech collaborated with Simcere Pharmaceuticals to accelerate the commercialization of a new generation of anti-influenza drug ADC189
On October 10, 2023, Simcere Pharmaceutical Group Ltd. (2096.HK) announced that they entered into a collaboration agreement with Jiaxing AnDiCon Biotech Co., Ltd. (AnDiCon) on the anti-influenza innovative drug ADC189.
Learn more
2023-09-20Medicilon Events
Medicilon's Interview: See how Dr. Chen Chen from ABM Therapeutics crosses the blood-brain barrier
Shanghai Medicilon Inc. (Medicilon) has the honor to invite Dr. Chen Chen, Founder and Chairman of ABM Therapeutics, to discuss the unique technical advantages and R&D strategies of ABM Therapeutics in developing brain-targeted drugs, as well as the inner journey and profound insights.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CAREERS
Talent Development
Employee Activities
Campus Recruitment
Social Recruitment
Campus Recruitment
Campus Recruitment
Social Recruitment
Social Recruitment
Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsFeatured Stories

Featured Stories

Hot information：
Top 10 Global CDMO Enterprises| Top 10 Global Clinical Research Organizations in 2021| The Meaning of IND, NDA and ANDA
Jun 12,2023
Medicilon's GLP-1 New Drug R&D Service
In the formulation of GLP-1 integrated research plan, Medicilon has in-depth communication with customers. Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services.
More
Medicilon's GLP-1 New Drug R&D Service
May 19,2023
Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates
Antibody-Oligonucleotide Conjugates (AOCs) represent an emerging class of functionalized antibodies that have already been used in a wide variety of applications. Following let us introduce the evolution of nucleic acid delivery technologies,Conjugation mechanism of AOC.
More
Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates
May 08,2023
Medicilon Flow Sorting Platform
Based on the technical basis of flow cytometry, the Medicilon flow sorting platform is widely used in scientific research and work in immunology, cell biology, oncology, hematology, drug development, and environmental testing. Medicilon flow cytometry team has extensive experience in experimental operation, flow sorting method development and data analysis.
More
Medicilon Flow Sorting Platform
May 08,2023
【Expert Report】Dr. Xingquan Ma: Medicinal Chemistry in Small Nucleic Acid Drug Discovery
On March 24, 2023, Dr. Xingquan Ma, SVP of the Chemistry Department of Medicilon, gave a report titled "Medicinal Chemistry in Small Nucleic Acid Drugs Discovery" during the IDC2023 4th Chemical New Drug and Improved New Drug R&D Forum. Medicilon can provide monomer synthesis and modification; oligonucleotide synthesis; delivery system synthesis and synthesis of oligonucleotide conjugates.
More
【Expert Report】Dr. Xingquan Ma: Medicinal Chemistry in Small Nucleic Acid Drug Discovery
May 04,2023
A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation
In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields.
More
A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp<sup>3</sup>-Sp<sup>2</sup> Bond Formation
Mar 03,2023
Whole-Process of Antibody Drug Development - Facilitate IND Declaration of Biological Drugs
The Medicilon antibody development platform has been deeply involved in the field of antibody drug research and development and their technical services include the ADA antibody development technical services and druggable antibody development technical services, ADA-free polyclonal antibody development, ADA mouse hybridoma monoclonal antibody development, phage display rabbit monoclonal antibody development services, mouse monoclonal antibody development technical services, mouse/rabbit single B cell antibody development technical services and other projects.
More
Whole-Process of Antibody Drug Development - Facilitate IND Declaration of Biological Drugs
Feb 24,2023
Beautiful Chemistry-Photoinduced Alkene Cleavage Using Nitroarenes
The oxidative cleavage of olefins is an important transformation in organic synthesis to obtain carbonyl functional groups such as ketones and aldehydes. Medicilon has integrated emerging methods of green chemistry into its services, using currently popular photoredox chemistry, electrochemisty, catalyst screening, continuous reactions, etc., to provide our customers with high-quality economic solutions.
More
Beautiful Chemistry-Photoinduced Alkene Cleavage Using Nitroarenes
Feb 17,2023
Come, Chat with ChatGPT regarding CRO
Almost overnight, the whole city chatted about ChatGPT. While people are admiring the omnipotence of AI, people also worry that their jobs will be taken away by AI one day...
More
Come, Chat with ChatGPT regarding CRO
Feb 17,2023
Market Prospects, Development Challenges and Countermeasures of Oligonucleotide Drugs
In recent years, with the advancement of related research and technology, nucleic acid drugs have ushered into rapid development, and the number of nucleic acid drugs approved for the global market is increasing yearly.
More
Market Prospects, Development Challenges and Countermeasures of Oligonucleotide Drugs
Feb 04,2023
World Cancer Day: Features of Popular Tumor Models in Oncology Drug Development
February 4th is the 24th World Cancer Day. Medicilon has been part of the great human effort to combat cancer since its founding in 2004. In order to better understand tumorigenesis, to foster cancer prevention and to develop novel anti- cancer therapy, Medicilon has been providing IND enabling preclinicalservice for 19 years, and has established close to 300 tumor evaluation model for R&D.
More
World Cancer Day: Features of Popular Tumor Models in Oncology Drug Development
Stock Code
688202

Global

Address: 50 Soldiers Field Place, Boston, MA 02135 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->